Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Ruthenium complex is an important compound group for antitumor drug research and development. NAMI-A, KP1019, TLD1433 and other ruthenium complexes have entered clinical research. In recent years, the research on ruthenium antitumor drugs has not been limited to single chemotherapy drugs; other applications of ruthenium complexes have emerged such as in combination therapy. During the development of ruthenium complexes, drug delivery forms of ruthenium antitumor drugs have also evolved from single-molecule drugs to nanodrug delivery systems. The review summarizes the following aspects: (1) ruthenium complexes from monotherapy to combination therapy, including the development of single-molecule compounds, carrier nanomedicine, and self-assembly of carrier-free nanomedicine; (2) ruthenium complexes in the process of ADME in terms of absorption, distribution, metabolism and excretion; (3) the applications of ruthenium complexes in combination therapy, including photodynamic therapy (PDT), photothermal therapy (PTT), photoactivated chemotherapy (PACT), immunotherapy, and their combined application; (4) the future prospects of ruthenium-based antitumor drugs.

Water soluble derivatives of platinum carbonyl Chini clusters: synthesis, molecular structures and cytotoxicity of [Pt12(CO)20(PTA)4]2- and [Pt15(CO)25(PTA)5]2-

The reactions of [Pt3n(CO)6n]2- (n = 2-5) homoleptic Chini-type clusters with increasing amounts of 1,3,5-triaza-7-phosphaadamantane (PTA) result in the stepwise substitution of one terminal CO ligand per Pt3 triangular unit up to the formation of [Pt3n(CO)5n(PTA)n]2- (n = 2-5). Competition between the nonredox substitution with retention of the nuclearity and the redox fragmentation to afford lower nuclearity heteroleptic Chini-type clusters is observed as a function of the amount of PTA and the nuclearity of the starting cluster. Because of this, [Pt12(CO)20(PTA)4]2- and [Pt15(CO)25(PTA)5]2- are more conveniently obtained via the oxidation of [Pt9(CO)15(PTA)3]2-. All the new species were spectroscopically characterized, and the structures of [Pt12(CO)20(PTA)4]2- and [Pt15(CO)25(PTA)5]2- were determined by single-crystal X-ray diffraction. These clusters may be viewed as heteroleptic Chini-type clusters composed of stacks of four and five Pt3(μ-CO)3(CO)2(PTA) units, respectively. The solubility in water of [Pt12(CO)20(PTA)4]2- and [Pt15(CO)25(PTA)5]2- has been determined and their cytotoxicity towards human ovarian (A2780) cancer cells and their cisplatin-resistant strain (A2780cisR) has been evaluated.

Flexible Modulation of CO-Release Using Various Nuclearity of Metal Carbonyl Clusters on Graphene Oxide for Stroke Remediation

Utilizing the size-dependent adsorption properties of ruthenium carbonyl clusters (Ru-carbon monoxide (CO)) onto graphene oxide (GO), a facile CO-release platform for in situ vasodilation as a treatment for stroke-related vascular diseases is developed. The rate and amount of formation of the CO-release-active Ru^II (CO)₂ species can be modulated by a simple mixing procedure at room temperature. The subsequent thermally induced oxidation of Ru^II (CO)₂ to RuO₂ on the GO surface results in the release of CO. Further modulation of thermal and CO-release properties can be achieved via a hybridization of medium- and high-nuclearity of Ru-CO clusters that produces a RuO₂ /Ru^II (CO)₂ /⁶ Ru-CO-GO composite, where ⁶ Ru-CO-GO provides a photothermally activated reservoir of Ru^II (CO)₂ species and the combined infrared absorption properties of GO and RuO₂ provides photothermal response for in situ CO-release. The RuO₂ /Ru^II (CO)₂ /⁶ Ru-CO-GO composite does not produce any cytotoxicity and the efficacy of the composite is further demonstrated in a cortical photothrombotic ischemia rat model.

Enhancement of biocompatibility and photoacoustic contrast activity of metal clusters

Organometallic carbonyl clusters (OMCC) of group VIII elements are water soluble, bio-compatible and stable high-contrast photoacoustic agents for live cell imaging. But, they have limited application due to weak absorption within 700-1000nm wavelength which is known as the biological window of absorption. In this article, we report that hexa-nuclear iron (Fe₆) carbonyl cluster derivatized with sodium thio-propanoate has very good absorption within 700-1600nm wave length. This modeled compound is water soluble and bio-compatible. The bio-compatibility of this compound is tested through cytotoxicity, LogP and metabolic probability at CYP450-2D6 enzyme.